Erythrodermic psoriasis (EP) is a severe, often refractory, variant of psoriasis. Due to the high morbidity and mortality rate associated with EP and other causes of erythroderma, they are often classified as dermatologic emergencies. EP is usually a therapeutic challenge, where topical and conventional systemic therapies have yielded a less than satisfactory result in several patients. Furthermore, there are a limited number of studies evaluating other therapeutic modalities, such as biologic agents, with no clear treatment guidelines. In this case report, we present a patient who was diagnosed as a case of EP and showed an impressive response to risankizumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459644 | PMC |
| http://dx.doi.org/10.1159/000525774 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Rare Presentation of Erythrodermic Psoriasis.
Cureus
December 2024
Psychology, University of Bath, Bath, GBR.
Erythrodermic psoriasis (EP) is a rare and challenging-to-diagnose severe form of psoriasis. Its presentation can have similarities with other inflammatory skin conditions, complicating subsequent management. We present a case of a 76-year-old woman with EP who presented with fever, tachycardia, leg swelling with pain and redness, and reduced consciousness.
View Article and Find Full Text PDFBiometrics and Biomarkers in Patients With Psoriasis.
Cureus
November 2024
Rheumatology, Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Davie, USA.
Psoriasis (PsO) is a chronic, systemic, and autoimmune dermatologic condition characterized by dry, scaly, and erythematous plaques on the skin. PsO can present in various forms, including guttate (small, round lesions commonly over the upper trunk and extremities that can be raised and scaly), inverse (smooth plaques of inflamed skin within skin folds of the groin, buttock, and breasts), pustular (white painful pustules within red inflamed blotches widespread over the body), and erythrodermic (red rash present over most of the body). Individuals with PsO can present differently, with unique symptoms and patterns on the skin.
View Article and Find Full Text PDFSingle-cell RNA sequencing of chronic idiopathic erythroderma defines disease-specific markers.
J Allergy Clin Immunol
December 2024
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
Background: Chronic erythroderma is a potentially life-threatening condition that can be caused by a variety of diseases, but approximately 30% of cases remain idiopathic, often with insufficient treatment options.
Objective: To establish a molecular disease map of chronic idiopathic erythroderma.
Methods: We performed single-cell RNA sequencing combined with T-cell receptor sequencing of blood and skin from 5 chronic idiopathic erythroderma (CIE) patients and compared results with 8 cases of erythrodermic cutaneous T-cell lymphoma (eCTCL), 15 moderate-to-severe atopic dermatitis (AD), 10 psoriasis and 20 healthy control (HC) individuals.
Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status.
J Cutan Pathol
December 2024
Department of Dermatology and Pathology, University of California, California, USA.
Background: Erythroderma is a dermatologic condition characterized by widespread red and scaly skin. The causes include, but are not limited to, psoriasis, eczema, drug eruptions, pityriasis rubra pilaris (PRP), and cutaneous T-cell lymphoma. Most of these are typified by Type 2 (e.
View Article and Find Full Text PDFArticle Synopsis
- - Deucravacitinib is a new oral medication approved in Japan for treating different types of psoriasis, including plaque, generalized pustular, and erythrodermic psoriasis.
- - The POETYK PSO-4 clinical trial involving 74 Japanese patients showed that the drug was effective and well tolerated, with significant improvements in psoriasis symptoms and quality of life over 52 weeks.
- - Results indicated that about two-thirds of patients achieved a Dermatology Life Quality Index score of 0 or 1 by week 52, although the small number of participants with generalized pustular or erythrodermic psoriasis makes it harder to draw broad conclusions for these types.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!